Radioactive Seeds Good Option for Many Prostate Cancer Patients, Research Shows - Cone Health

Skip to Content

Published on May 30, 2012

Radioactive Seeds Good Option for Many Prostate Cancer Patients, Research Shows

Doctors at Cone Health Cancer Center find treating prostate cancer with radioactive seeds to be superior and more cost effective than other treatment options. The findings were unveiled during a recent cancer symposium at Cone Health Cancer Center.

Cone Health Cancer Center has treated more than 2,000 patients with seed implants and is the highest volume robotic prostate implant center in the U.S. Physicians at Cone Health Cancer Center have been using prostate seed implants for 20 years to treat prostate cancer, one of the most common cancers in American men.

U.S. Government Photo

“There are many advantages to prostate seed implants,” says Dr. Robert Murray, Radiation Oncologist, Cone Health Cancer Center. “It is relatively non-invasive, can be done in 1-2 hours and there is little to no recovery time for the patient.”

Prostate seed implantation is often called brachytherapy. In the procedure, rice grain sized tubes of iodine 125, a radioactive agent, are inserted in the prostate. Extensive work is done beforehand to figure out exactly where to place the radioactive seeds to kill each patient’s individual cancer most effectively. Doctors use a robotic system to more accurately place the seeds. Iodine 125 targets the prostate cancer with a low energy dosage, meaning there is little radiation exposure in nearby tissues.

The use of brachytherapy in treating prostate cancer was just one of the presentations at the recent John Lusk Cone Health Inaugural Oncology Symposium. The symposium brought 72 medical professionals from across North Carolina to the Cone Health Cancer Center on the Wesley Long Hospital campus to learn the latest in cancer care focusing on the unique technology and experience of Cone Health Cancer Center.

Other topics included presentations on TomoTherapy® and TrueBeam STx radiation therapies, two of Cone Health’s leading-edge radiation treatments, as well as on the emerging science of survivorship as emphasized by the Breast Cancer Alliance. The Alliance is a weekly meeting of oncologists, diagnostic radiologists, pharmacists, surgeons, pathologists and others who review new breast cancer cases at Cone Health to offer the most comprehensive, state-of-the-art and individualized treatment for each case.

“This was a great chance to share with our peers the oncology expertise we have in this community,” says Skip Hislop, Vice President for Oncology Services, Cone Health. “Offering the Oncology Symposium is one of the many steps we are taking to make people aware that Cone Health Cancer Center provides exceptional care and is at the forefront of cancer facilities.”

Health Resources

Click to Expand

Media Inquiries

For media inquiries related to Cone Health, contact:

Doug Allred
External Communications Manager
(336) 832-8659

On Twitter: @ConeHealthPR